A B Beckers1, D Keszthelyi1, A Fikree2, L Vork1, A Masclee1, A D Farmer2,3, Q Aziz2. 1. Division of Gastroenterology-Hepatology, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, The Netherlands. 2. Wingate Institute of Neurogastroenterology, Centre for Digestive Diseases, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK. 3. Department of Gastroenterology, University Hospitals of North Midlands, Stoke on Trent, Staffordshire, UK.
Abstract
BACKGROUND: Joint hypermobility syndrome (JHS)/Ehlers-Danlos syndrome hypermobility type (EDS-HT) is the most common hereditary non-inflammatory disorder of connective tissue, characterized by a wide range of symptoms, mainly joint hyperextensibility and musculoskeletal symptoms. A majority of patients also experiences gastrointestinal (GI) symptoms. Furthermore, JHS/EDS-HT has specifically been shown to be highly prevalent in patients with functional GI disorders, such as functional dyspepsia and irritable bowel syndrome. PURPOSE: The aim of this review was to examine the nature of GI symptoms and their underlying pathophysiology in JHS/EDS-HT. In addition, we consider the clinical implications of the diagnosis and treatment of JHS/EDS-HT for practicing clinicians in gastroenterology. Observations summarized in this review may furthermore represent the first step toward the identification of a new pathophysiological basis for a substantial subgroup of patients with functional GI disorders.
BACKGROUND:Joint hypermobility syndrome (JHS)/Ehlers-Danlos syndrome hypermobility type (EDS-HT) is the most common hereditary non-inflammatory disorder of connective tissue, characterized by a wide range of symptoms, mainly joint hyperextensibility and musculoskeletal symptoms. A majority of patients also experiences gastrointestinal (GI) symptoms. Furthermore, JHS/EDS-HT has specifically been shown to be highly prevalent in patients with functional GI disorders, such as functional dyspepsia and irritable bowel syndrome. PURPOSE: The aim of this review was to examine the nature of GI symptoms and their underlying pathophysiology in JHS/EDS-HT. In addition, we consider the clinical implications of the diagnosis and treatment of JHS/EDS-HT for practicing clinicians in gastroenterology. Observations summarized in this review may furthermore represent the first step toward the identification of a new pathophysiological basis for a substantial subgroup of patients with functional GI disorders.
Authors: Konstantinos C Fragkos; Katie Keetarut; Anna Cox; Johanna Eady; Anton V Emmanuel; Natalia Zarate-Lopez Journal: Gastroenterology Res Date: 2019-02-26
Authors: Jeremy M D Nightingale; Peter Paine; John McLaughlin; Anton Emmanuel; Joanne E Martin; Simon Lal Journal: Gut Date: 2020-08-21 Impact factor: 23.059
Authors: Abraham B Beckers; Lisa Vork; Asma Fikree; Rogier de Ridder; Qasim Aziz; Ad Masclee; Daniel Keszthelyi Journal: Therap Adv Gastroenterol Date: 2020-07-17 Impact factor: 4.409
Authors: Ditte S Kornum; Astrid J Terkelsen; Davide Bertoli; Mette W Klinge; Katrine L Høyer; Huda H A Kufaishi; Per Borghammer; Asbjørn M Drewes; Christina Brock; Klaus Krogh Journal: J Clin Med Date: 2021-03-31 Impact factor: 4.241